DE60027608D1 - Mesalazine enthaltende pharmazeutische Zusammensetzungen mit gesteuerter Freisetzung - Google Patents

Mesalazine enthaltende pharmazeutische Zusammensetzungen mit gesteuerter Freisetzung

Info

Publication number
DE60027608D1
DE60027608D1 DE60027608T DE60027608T DE60027608D1 DE 60027608 D1 DE60027608 D1 DE 60027608D1 DE 60027608 T DE60027608 T DE 60027608T DE 60027608 T DE60027608 T DE 60027608T DE 60027608 D1 DE60027608 D1 DE 60027608D1
Authority
DE
Germany
Prior art keywords
pharmaceutical compositions
mesalazine
controlled release
release pharmaceutical
containing controlled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60027608T
Other languages
English (en)
Other versions
DE60027608T2 (de
Inventor
Roberto Villa
Massimo Pedrani
Mauro Ajani
Lorenzo Fossati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cosmo Technologies Ltd
Original Assignee
Cosmo Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11383159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60027608(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cosmo Technologies Ltd filed Critical Cosmo Technologies Ltd
Application granted granted Critical
Publication of DE60027608D1 publication Critical patent/DE60027608D1/de
Publication of DE60027608T2 publication Critical patent/DE60027608T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
DE60027608T 1999-06-14 2000-06-08 Mesalazine enthaltende pharmazeutische Zusammensetzungen mit gesteuerter Freisetzung Expired - Lifetime DE60027608T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999MI001316A ITMI991316A1 (it) 1999-06-14 1999-06-14 Composizioni farmaceutiche orali a rilascio modificato di mesalazina
ITMI991316 1999-06-14

Publications (2)

Publication Number Publication Date
DE60027608D1 true DE60027608D1 (de) 2006-06-01
DE60027608T2 DE60027608T2 (de) 2007-04-26

Family

ID=11383159

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60001835T Expired - Lifetime DE60001835T2 (de) 1999-06-14 2000-06-08 Mesalazine enthaltende pharmazeutische zusammensetzungen mit gesteuerte freisetzung
DE60027608T Expired - Lifetime DE60027608T2 (de) 1999-06-14 2000-06-08 Mesalazine enthaltende pharmazeutische Zusammensetzungen mit gesteuerter Freisetzung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60001835T Expired - Lifetime DE60001835T2 (de) 1999-06-14 2000-06-08 Mesalazine enthaltende pharmazeutische zusammensetzungen mit gesteuerte freisetzung

Country Status (18)

Country Link
US (1) US6773720B1 (de)
EP (2) EP1287822B1 (de)
JP (2) JP4727875B2 (de)
CN (2) CN100448448C (de)
AT (2) ATE235234T1 (de)
AU (1) AU5077200A (de)
CA (1) CA2377299C (de)
DE (2) DE60001835T2 (de)
DK (2) DK1287822T3 (de)
ES (2) ES2194732T3 (de)
HK (2) HK1046247B (de)
IT (1) ITMI991316A1 (de)
MX (1) MXPA01012888A (de)
NO (1) NO329402B1 (de)
PT (2) PT1198226E (de)
RU (1) RU2245148C2 (de)
TR (1) TR200200561T2 (de)
WO (1) WO2000076481A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895064B2 (en) 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
AU5680100A (en) 1999-06-14 2001-01-02 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US8282955B2 (en) 2001-10-15 2012-10-09 Ferring B.V. Method for the preparation of a pharmaceutical composition comprising 5-aminosalicylic acid for use in treatment of ulcerative colitis and Crohn's disease
ITMI20012599A1 (it) * 2001-12-11 2003-06-11 Cosmo Spa Composizioni farmaceutiche per la somministrazione orale di eparina osuoi derivati, utili per la terapia di malattie infiammatorie dell'int
US9308220B2 (en) 2001-12-11 2016-04-12 Cosmo Technologies Limited Pharmaceutical compositions for the oral administration of heparin or derivatives thereof
US20030118329A1 (en) * 2001-12-21 2003-06-26 Pere Obrador Video indexing using high resolution still images
KR100540035B1 (ko) * 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
FR2852843B1 (fr) 2003-03-24 2008-05-23 Karim Ioualalen Systeme galenique permettant le masquage du gout
CA2520197A1 (en) * 2003-04-23 2004-11-04 Ferring B.V. Sachet for a pharmaceutical composition
US7825106B2 (en) * 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
US7737133B2 (en) 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
GB0322848D0 (en) * 2003-09-30 2003-10-29 Alpharma Ltd Tetracycline controlled release pharmaceutical dosage form
US20050152974A1 (en) * 2003-12-31 2005-07-14 Garth Boehm Atomoxetine formulations
US7417037B2 (en) 2004-01-20 2008-08-26 The Board Of Regents Of The University Of Oklahoma Compositions and methods of treatment for inflammatory diseases
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US7700651B2 (en) 2006-07-19 2010-04-20 The Board Of Regents Of The University Of Texas System Preparations of phospholipids and pharmaceuticals containing 5-amino salicylic acid for the treatment of inflammatory bowel disease
MX2009002785A (es) * 2006-09-13 2009-03-30 Procter & Gamble Metodos para el tratamiento de la colitis ulcerosa.
CA2662430A1 (en) * 2006-09-13 2008-03-20 The Procter & Gamble Company Methods of treatment for ulcerative colitis using aminosalicylate
AU2007321906A1 (en) 2006-11-17 2008-05-29 Shire Development Inc. Method of treatment for inflammatory bowel disease
FR2913884A1 (fr) * 2007-03-21 2008-09-26 Oralance Pharma Sa Systeme galenique hydrophobe non ionisable
US20090028944A1 (en) * 2007-07-16 2009-01-29 Balaji Sathurappan Pharmaceutical compositions comprising mesalamine
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
US20090169622A1 (en) * 2007-12-27 2009-07-02 Roxane Laboratories, Inc. Delayed-release oral pharmaceutical composition for treatment of colonic disorders
US20110097401A1 (en) 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
WO2011045775A1 (en) * 2009-10-16 2011-04-21 Ranbaxy Laboratories Limited A delayed release pharmaceutical composition of mesalamine
IT1398643B1 (it) 2010-03-04 2013-03-08 Cosmo Technologies Ltd Composizione solida per la somministrazione orale di coloranti, e utilizzo diagnostico della stessa
EP2425826A1 (de) * 2010-09-01 2012-03-07 Disphar International B.V. Mesalazin-Tablette mit verbesserter Auflösung
IT1402047B1 (it) * 2010-10-19 2013-08-28 Cross Pharma Sa Uso del mexiprostil nel trattamento delle malattie infiammatorie intestinali
EP2468264A1 (de) 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Orale pharmazeutische Tablette zur gesteuerten Abgabe von Mesalazin und Verfahren zu deren Erhalt
DK2661266T3 (da) 2011-01-07 2020-11-16 Anji Pharma Us Llc Kemosensoriske receptorligandbaserede terapier
US9795792B2 (en) 2011-02-25 2017-10-24 Medtronic, Inc. Emergency mode switching for non-pacing modes
US10154964B2 (en) 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
AU2012363873B2 (en) 2012-01-06 2017-11-23 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
EA033067B1 (ru) 2012-01-06 2019-08-30 Элселикс Терапьютикс, Инк. Способ лечения метаболических расстройств у пациента, имеющего противопоказание к назначению бигуанидного соединения
WO2013134348A1 (en) * 2012-03-07 2013-09-12 Santarus, Inc. Controlled-release solid dosage forms of mesalamine
WO2013144176A1 (en) 2012-03-30 2013-10-03 Laboratorios Del Dr. Esteve, S.A. Controlled release formulatin comprising mesalamine
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
JP2015522080A (ja) 2012-07-11 2015-08-03 エルセリクス セラピューティクス インコーポレイテッド スタチン、ビグアナイド、およびさらなる薬剤を含む心血管代謝性リスクを減少させるための組成物
EP2722058A1 (de) 2012-10-19 2014-04-23 Cosmo Technologies Ltd Orale Feststoffzusammensetzung mit Farbstoffen für die Verwendung bei der endoskopischen Diagnose
EP2941245A1 (de) 2013-01-05 2015-11-11 Elcelyx Therapeutics, Inc. Retard-zusammensetzung mit biguanid
TWI688411B (zh) * 2013-02-22 2020-03-21 日商志瑞亞新藥工業股份有限公司 腸溶錠
EP2953619A1 (de) 2013-03-15 2015-12-16 Warner Chilcott Company, LLC Pharmazeutische mesalaminzusammensetzung mit mehrfachdosierungselemente für reduzierte abgabevariabilität
US9539265B2 (en) 2013-03-15 2017-01-10 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
CN104922090B (zh) * 2015-07-03 2017-11-14 湖南方盛制药股份有限公司 美沙拉秦肠溶缓释微丸
EP3162362A1 (de) 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimierte mesalazinhaltige hochdosistablette
ITUA20162293A1 (it) 2016-04-05 2017-10-05 Sofar Spa Processo per formulazioni solide di mesalazina
US20200061212A1 (en) 2016-11-28 2020-02-27 Cosmo Technologies Ltd. Solid oral composition containing dyes
US10098898B1 (en) 2017-12-04 2018-10-16 Handa Pharmaceuticals, Llc Release stable mesalamine dosage forms
EP3501503A1 (de) * 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Feste verabreichungszusammensetzung
EP3662895A1 (de) 2018-12-07 2020-06-10 Tillotts Pharma AG Verfahren zur herstellung von reduzierenden zuckerfreien 5-asa-tablettenkernen
IT201800011120A1 (it) 2018-12-14 2020-06-14 Dpl Pharma S P A Composizioni farmaceutiche orali solide per la somministrazione di mesalazina o suoi derivati
CN112587506A (zh) * 2020-12-09 2021-04-02 南京森博医药研发有限公司 一种用于制备美沙拉嗪肠溶缓释胶囊的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921757A (en) * 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
JPS6248618A (ja) * 1985-08-27 1987-03-03 Zeria Shinyaku Kogyo Kk 徐放性製剤およびその製造法
JP2893191B2 (ja) * 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
IL92343A0 (en) * 1988-12-20 1990-07-26 Gist Brocades Nv Granulate for multiparticulate controlled release oral compositions,their preparation and oral pharmaceutical compositions containing them
IL92344A0 (en) * 1989-01-04 1990-07-26 Gist Brocades Nv Microencapsulation of bioactive substances in biocompatible polymers,microcapsules obtained and pharmaceutical preparation comprising said microcapsules
JPH02282323A (ja) * 1989-04-21 1990-11-19 Shin Etsu Chem Co Ltd 徐放性錠剤の製造方法
JPH03232814A (ja) * 1990-02-08 1991-10-16 Shin Etsu Chem Co Ltd 徐放性錠剤の製造方法
IE61651B1 (en) * 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
JP3011752B2 (ja) * 1990-10-23 2000-02-21 フロイント産業株式会社 徐放性製剤およびその製造方法
JP2829794B2 (ja) * 1991-02-08 1998-12-02 エスエス製薬 株式会社 徐放性経口投与型プラノプロフェン製剤
GEP19971086B (en) * 1991-02-22 1997-12-02 Tillotts Pharma Ag Peroral Pharmaceutically Dispensed Form for Selective Introducing of the Medicine into the Intestine
JPH0624962A (ja) * 1992-07-09 1994-02-01 Green Cross Corp:The 腸溶徐放性製剤
ATE223704T1 (de) * 1992-10-16 2002-09-15 Nippon Shinyaku Co Ltd Verfahren zur herstellung von wachsmatrizes
US5911980A (en) * 1996-06-27 1999-06-15 Macrochem Corporation Lipophilic and amphiphilic or hydrophilic film-forming polymer compositions, and use thereof in topical agent delivery system and method of delivering agents to the skin
AU5775398A (en) * 1996-12-17 1998-07-15 Poli Industria Chimica S.P.A. Site-specific controlled release dosage formulation for mesalamine
US5851555A (en) * 1997-08-15 1998-12-22 Fuisz Technologies Ltd. Controlled release dosage forms containing water soluble drugs
AU5680100A (en) * 1999-06-14 2001-01-02 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions

Also Published As

Publication number Publication date
ATE235234T1 (de) 2003-04-15
NO20016107D0 (no) 2001-12-14
JP2003501458A (ja) 2003-01-14
JP5235839B2 (ja) 2013-07-10
WO2000076481A1 (en) 2000-12-21
EP1287822A2 (de) 2003-03-05
HK1085669A1 (en) 2006-09-01
DE60001835D1 (de) 2003-04-30
DE60027608T2 (de) 2007-04-26
JP2010024241A (ja) 2010-02-04
PT1198226E (pt) 2003-07-31
EP1287822B1 (de) 2006-04-26
EP1287822A3 (de) 2003-03-19
NO20016107L (no) 2002-02-11
ES2194732T3 (es) 2003-12-01
HK1046247A1 (en) 2003-01-03
NO329402B1 (no) 2010-10-11
CN1355694A (zh) 2002-06-26
US6773720B1 (en) 2004-08-10
CN1217665C (zh) 2005-09-07
EP1198226B1 (de) 2003-03-26
PT1287822E (pt) 2006-07-31
HK1046247B (zh) 2006-04-07
EP1198226A1 (de) 2002-04-24
MXPA01012888A (es) 2002-07-30
JP4727875B2 (ja) 2011-07-20
ATE324104T1 (de) 2006-05-15
CN100448448C (zh) 2009-01-07
CA2377299A1 (en) 2000-12-21
ITMI991316A1 (it) 2000-12-14
CA2377299C (en) 2009-05-12
DK1198226T3 (da) 2003-07-21
ES2262749T3 (es) 2006-12-01
AU5077200A (en) 2001-01-02
CN1720919A (zh) 2006-01-18
ITMI991316A0 (it) 1999-06-14
DE60001835T2 (de) 2003-11-13
TR200200561T2 (tr) 2002-06-21
RU2245148C2 (ru) 2005-01-27
DK1287822T3 (da) 2006-08-28

Similar Documents

Publication Publication Date Title
DE60001835T2 (de) Mesalazine enthaltende pharmazeutische zusammensetzungen mit gesteuerte freisetzung
RU2002102701A (ru) Стабильная пероральная образующая гидрогель, фармацевтическая композиция, способ ее получения, способ предотвращения изменений высвобождения лекарственного средства, способ увеличения физической стабильности пероральной композиции
DE68909772T2 (de) Diclofenac-Natrium-Arzneizubereitung mit verlängerter Wirkstoffabgabe.
DE60211464D1 (de) Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer, sowie deren herstellung
ATE79538T1 (de) Dispergierbare zubereitung.
DE59907481D1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
IT1284604B1 (it) Composizioni farmaceutiche a rilascio controllato per somministrazione orale contenenti nifedipina come sostanza attiva
DE69831940D1 (de) Tablette mit verlängerter Wirkstoffabgabe im Magen
DE69710121D1 (de) Pharmazeutische Zusammensetzung aus stabilisierten lipophilen Matrizen mit kontrollierter Wirkstofffreisetzung
ES2086576T3 (es) Formulaciones de liberacion sostenida de acetazolamida.
AR034435A1 (es) Agentes terapeuticos.
ES2169980B1 (es) Microcapsulas para la liberacion prolongada de farmacos.
ATE335491T1 (de) Arzneimittel gegen glomerulosclerose
ITMI20000972A0 (it) Formulazioni farmaceutiche, a rilascio modificato, con elevata biodisponibilita', contenenti principi attivi ad attivita' antibiotica.
IT8922398A0 (it) Composizioni farmaceutiche ad elevato assorbimento e stabilita', comprendente una calcitonina come sostanza attiva.
CO4910116A1 (es) Formulacion de liberacion controlada para farmacos basicos escasamente solubles
DE60115450D1 (de) Pirlindolhydrochlorid-Matrixformulierungen mit verlängerter Wirkstofffreigabe
PA8531801A1 (es) Formulaciones estabilizadas que comprenden composiciones hidroliticamente inestables